Adimmune Corporation (TWSE: 4142) announced during the institutional investor conference today that Adimmune has submitted the application for marketing authorization of its quadrivalent influenza vaccine to Brazilian ANVISA in November, marking its official initiation for entry into the Southern Hemisphere’s influenza market. Another significant development is that Adimmune has successfully resumed production of its tetanus vaccine in Taiwan, and the supply has generated positive reception in the domestic market. The demand of tetanus vaccine is also strong in Southeast Asia and China, and Adimmune may anticipate a promising leap in export sales once the tetanus vaccine is approved in those markets. Building on its current CDMO performance, Adimmune foresees expanding partnership with bio-pharmaceutical manufacturers in Korea and France and expects to realize substantial growth in 2024.

In 2023, Adimmune provided 3.5 million doses of influenza vaccine to the local public tender market in Taiwan. Its influenza vaccine is also distributed to Eastern Europe, China, and Thailand. Additionally, following the marketing authorization approval by ANVISA, Adimmune will be capable of manufacturing and supplying influenza vaccines for both the northern and southern hemispheres, maintaining a year-round influenza production line.

Adimmune’s new tetanus vaccine facility, constructed in compliance with PIC/S GMP and U.S. FDA standards, has an annual capacity of at least 5 million doses. Critical supply shortages of tetanus vaccine in Taiwan were promptly addressed. While maintaining a pivotal role in fulfilling Taiwan’s epidemic prevention needs, Adimmune also has available production capacity for export markets.

A recent announcement in China emphasized the mandatory medical response for dog bites, requiring the administration of both rabies and tetanus vaccines. With an annual demand for 60 million doses in China and only two domestic manufacturers, there is a substantial shortage of tetanus vaccine supply. Recognizing this urgent need, Adimmune has formulated strategy to export tetanus vaccines to overseas markets including China and Southeast Asia. Anticipating a substantial growth in tetanus vaccine sales next year, Adimmune aims to become a leading supplier, addressing critical medical shortages both domestically and internationally. On the other hand, Adimmune has developed a single-dose syringe tetanus vaccine, simplifying the extraction process particularly for emergency and clinical applications.

To overcome the manufacturing capacity limitations of the enterovirus 71 vaccine at Adimmune’s facility in National Health Research Institutes in Chunan, the Company has commenced the transfer of the production to Adimmune’s Tanzi cell culture plant and has submitted a request for an on-site inspection by the FDA. The line relocation is expected to be completed in Q4 of 2024. Meanwhile, the Phase III clinical trial of Enimmune’s EV71 vaccine in Vietnam has completed the enrollment. The comprehensive efficacy evaluation report is expected to be available by Q3 of 2024.

Among international turbulence and unforeseen cuts in CDMO orders, this year’s performance fell short of initial expectations. However, the company has strategically partnered with BD, a prominent international syringe manufacturer, and the WEGO Group, a major manufacturer in medical materials. Collaborating with WEGO, Adimmune is actively pushing its own-brand products—such as influenza, tetanus, and, EV 71 vaccines—into the South East Asian market. Further cooperation in establishing manufacturing facilities in South East Asia is under discussion, aligning with Adimmune’s goal of globalization, to amplify the presence of Adimmune and technological advancements.